Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 7, 2018
OPKO Health, Inc.
(Exact Name of Registrant as Specified in Charter)
|
| | | | |
Delaware | | 001-33528 | | 75-2402409 |
(State or Other Jurisdiction of Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
|
| | |
4400 Biscayne Blvd. Miami, Florida | | 33137 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (305) 575-4100
|
|
Not Applicable |
Former name or former address, if changed since last report |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
|
| | |
ITEM 7.01. | | Regulation FD Disclosure.
|
On September 11, 2018, OPKO Health, Inc. (“OPKO” or the “Company”) issued a press release regarding Nasdaq’s decision to halt trading in OPKO’s common stock in connection with the lawsuit previously reported in the Company’s Current Report on Form 8-K filed on September 10, 2018 (the “Lawsuit”). A copy of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference. The information included in this Item 7.01 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
On September 7, 2018, at 14:34:38 Eastern Daylight Time, Nasdaq halted trading in the Company’s common stock pending receipt from the Company of information requested by the exchange related to the allegations contained in the Lawsuit. Nasdaq has advised the Company that trading will remain halted until the exchange is satisfied with OPKO’s response to Nasdaq’s request for information
|
| | |
ITEM 9.01. | | Financial Statements and Exhibits. |
|
| | |
| | |
Exhibit No. | | Description |
| |
99.1 | | Press Release of the Company dated September 11, 2018 |
Exhibit List
|
| | |
| | |
Exhibit No. | | Description |
| |
99.1 | | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | |
| | OPKO Health, Inc. |
| | | |
| | By: | /s/ Adam Logal |
Date: September 11, 2018 | | Name: | Adam Logal |
| | Title: | Senior Vice President, Chief Financial Officer |
| | | |